{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:01:41Z","timestamp":1780506101554,"version":"3.54.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,18]]},"DOI":"10.7759\/cureus.71759","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T09:56:21Z","timestamp":1729245381000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-Induced Addison\u2019s Disease Leading to Severe Hyponatremia in a Breast Cancer Survivor: A Case Report With Implications for Emergency Department Practice"],"prefix":"10.7759","author":[{"given":"\u00d6merul F","family":"Aydin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14761","article-title":"Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer","volume":"14","author":"Kurokawa K","year":"2023","unstructured":"Kurokawa K, Mitsuishi Y, Shimada N, et al.. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer. Thorac Cancer. 2023, 14:442-9. 10.1111\/1759-7714.14761","journal-title":"Thorac Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-024-00332-2","article-title":"Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report","volume":"10","author":"Fujimiya T","year":"2024","unstructured":"Fujimiya T, Azuma K, Togashi Y, Kuwata K, Unezaki S, Takeuchi H. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. J Pharm Health Care Sci. 2024, 10:10. 10.1186\/s40780-024-00332-2","journal-title":"J Pharm Health Care Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-016-0426-9","article-title":"Severe hyponatremia and immune nephritis following an initial infusion of nivolumab","volume":"11","author":"Vandiver JW","year":"2016","unstructured":"Vandiver JW, Singer Z, Harshberger C. Severe hyponatremia and immune nephritis following an initial infusion of nivolumab. Target Oncol. 2016, 11:553-6. 10.1007\/s11523-016-0426-9","journal-title":"Target Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363:711-23. 10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.34","article-title":"Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma","volume":"29","author":"Romach MK","year":"1981","unstructured":"Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM. Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther. 1981, 29:211-7. 10.1038\/clpt.1981.34","journal-title":"Clin Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al.. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015, 372:320-30. 10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/293730-pembrolizumab-induced-addisons-disease-leading-to-severe-hyponatremia-in-a-breast-cancer-survivor-a-case-report-with-implications-for-emergency-department-practice","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T09:56:22Z","timestamp":1729245382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/293730-pembrolizumab-induced-addisons-disease-leading-to-severe-hyponatremia-in-a-breast-cancer-survivor-a-case-report-with-implications-for-emergency-department-practice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.71759","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}